Amgen Gobbles Up Micromet In $1.16 Billion BiTE
This article was originally published in The Pink Sheet Daily
Executive Summary
With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).
You may also be interested in...
136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure
The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.
Deal Watch: Amgen BiTEs Back Micromet-Developed Boehringer Antibody
Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.
Amgen Bispecific Antibody Blincyto Gets Green Light From Europe’s CHMP
The acute lymphoblastic leukemia therapy, already available in the US, was recommended for a conditional approval in Europe to speed early patient access.